Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Focus Minnesota.
Press releases published on May 14, 2025
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
GlobeNewswire
·
May 14, 2025
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy …
Monogram Technologies Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World’s First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time …
MDxHealth Reports Q1-2025 Results
GlobeNewswire
·
May 14, 2025
Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q…
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
GlobeNewswire
·
May 14, 2025
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ …
US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030
GlobeNewswire
·
May 14, 2025
Delhi, May 14, 2025 (GLOBE NEWSWIRE) -- US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights: US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030 …
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
GlobeNewswire
·
May 14, 2025
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and 80 mg dose levels and longer duration SAN DIEGO and …
Sevaro Launches Nationwide Stroke Awareness Campaign With Racecars, Storybooks, and Student Heroes
GlobeNewswire
·
May 14, 2025
CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- A stroke happens every 40 seconds in the U.S.—and every minute without treatment can cost a person 1.9 million brain cells. This May, during Stroke Awareness Month Sevaro Health is shifting the narrative— …
The Best Steroids for Cutting, Muscle Growth & Strength for Weight Training - Top Legal Steroid Stacks for Bulking, Fat Loss, Getting Shredded & Ripped - CrazyBulk
GlobeNewswire
·
May 14, 2025
New York City, NY, May 14, 2025 (GLOBE NEWSWIRE) -- For serious bodybuilders and weightlifters, achieving fast muscle growth and that shredded look takes more than just hard work in the gym. The right steroid stack will push past limits, pack on lean …
REPEAT/Media Advisory/OHC - Day of Action at Ontario Legislature to Stop Hospital Closures
GlobeNewswire
·
May 14, 2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- On Wednesday May 14, people from across Ontario will be heading into the Ontario Legislature for a “Day of Action” to ask the Ford government to stop closing their local hospitals and to provide the resources …
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire
·
May 14, 2025
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- …
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
GlobeNewswire
·
May 14, 2025
- Angelini Ventures and Apollo Health Ventures join existing top-tier investor syndicate - Follows original $36M Series A raise and brings Series A total to $75M - Proceeds are being used to fund Phase 1b Alzheimer’s and DME studies, and bispecific …
Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
GlobeNewswire
·
May 14, 2025
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a …
“Say the ‘S’ word:” Physician-Patient Alliance for Health & Safety Launches CME Sepsis Courses
GlobeNewswire
·
May 14, 2025
Chicago, IL, May 14, 2025 (GLOBE NEWSWIRE) -- “Say the ‘S’ word:” Physician-Patient Alliance for Health …
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
GlobeNewswire
·
May 14, 2025
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter …
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
GlobeNewswire
·
May 14, 2025
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
GlobeNewswire
·
May 14, 2025
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., …
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
GlobeNewswire
·
May 14, 2025
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional …
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire
·
May 14, 2025
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of …
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
GlobeNewswire
·
May 14, 2025
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different …
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event
GlobeNewswire
·
May 14, 2025
Live webcast followed by an interactive Q…